Comparison of Long-term Human Precision-cut Lung Slice Culture Methodology and Response to Challenge: An Argument for Standardisation.

animal replacement human hPCLS inhalation toxicology lung disease respiratory research tissue culture

Journal

Alternatives to laboratory animals : ATLA
ISSN: 0261-1929
Titre abrégé: Altern Lab Anim
Pays: England
ID NLM: 8110074

Informations de publication

Date de publication:
Sep 2021
Historique:
pubmed: 28 11 2021
medline: 15 12 2021
entrez: 27 11 2021
Statut: ppublish

Résumé

As non-animal alternatives gain acceptance, a need for harmonised testing strategies has emerged. Arguably the most physiologically-relevant model for assessing potential respiratory toxicants, that based on human precision-cut lung slices (hPCLS) has been utilised in many laboratories, but a variety of culture methodologies are employed. In this pilot study, combinations of three different hPCLS culture methods (dynamic organ roller culture (DOC), air-liquid interface (ALI) and submersion) and various media (based on E-199, DMEM/F12 and RPMI-1640) were compared. The hPCLS were assessed in terms of their viability and responsiveness to challenge. The endpoints selected to compare the medium-method (M-M) combinations, which included histological features and viability, were evaluated at day 14 (D14) and day 28 (D28); protein and adenylate kinase (AK) content, and cytokine response to immunostimulants (lipopolysaccharide (LPS) at 5 μg/ml; polyinosinic:polycytidylic acid (Poly I:C) at 15 μg/ml) were evaluated at D28 only. Based on the set of endpoints assessed at D28, it was clear that certain culture conditions significantly affected the hPCLS, with the tissue retaining more of its native features and functionality (in terms of cytokine response) in some of the M-M combinations tested more than others. This pilot study indicates that the use of appropriate M-M combinations can help maintain the health and functional responses of hPCLS, and highlights the need for the standardisation of culture conditions in order to facilitate effective inter-laboratory comparisons and encourage greater acceptance by the regulatory community.

Identifiants

pubmed: 34836458
doi: 10.1177/02611929211061884
doi:

Substances chimiques

Lipopolysaccharides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

209-222

Auteurs

Vivek Patel (V)

Respiratory Toxicology, 329003Institute for In Vitro Sciences, Inc., Gaithersburg, MD, USA.

Khalid Amin (K)

Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.

David Allen (D)

Integrated Laboratory Systems, Inc., Morrisville, NC, USA.

Lindsey Ukishima (L)

Respiratory Toxicology, 329003Institute for In Vitro Sciences, Inc., Gaithersburg, MD, USA.

Adam Wahab (A)

Respiratory Toxicology, 329003Institute for In Vitro Sciences, Inc., Gaithersburg, MD, USA.

Chad Grodi (C)

Respiratory Toxicology, 329003Institute for In Vitro Sciences, Inc., Gaithersburg, MD, USA.

Holger Behrsing (H)

Respiratory Toxicology, 329003Institute for In Vitro Sciences, Inc., Gaithersburg, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH